JBM  Vol.5 No.12 , December 2017
Clinical Pathological Analysis in 104 Ductal Breast Cancer Cases
Ductal breast cancer is a clinically heterogeneous disease; we investigate the correlation between tumor size, comedo necrosis, number of cell mitoses and axillary lymph node metastasis in ductal breast cancer. In this study, 104 ductal breast cancer specimens were collected and divided into 3 groups: T1 group (tumor size ≤ 2 cm), T2 group (2 < tumor size ≤ 5 cm) and T3 group (tumor size > 5.0 cm). Among those specimens, 95 cases were diagnosed with invasive ducted carcinoma, and 9 cases were ductal carcinoma in-situ (DCIS). Results show that T3 group has a higher rate of axillary lymph node metastasis than T2 group and T1 group; T2 group has a higher rate of lymph node metastasis than T1 group. The patients with the number of cell mitoses (≥10) were also has a higher rate of axillary lymph node metastasis (P = 0.0139) than the patients with the number of cell mitoses (<10). No significance was found between comedo necrosis lesions and axillary lymph node metastasis, though the frequency of comedo necrosis lesions in patients with axillary lymph node metastasis was higher than those in non-metastatic patients. It is concluded that the tumor size and the number of cell mitoses were risk factors for axillary lymph node involvement in ductal breast cancer.
Cite this paper: Jin, Y. , Huang, X. , Li, Y. , Li, X. and Dai, Z. (2017) Clinical Pathological Analysis in 104 Ductal Breast Cancer Cases. Journal of Biosciences and Medicines, 5, 37-43. doi: 10.4236/jbm.2017.512005.

[1]   Rosa Mendoza, E.S., Moreno, E. and Caguioa, P.B. (2013) Predictors of Early Distant Metastasis in Women with Breast Cancer. J Cancer Res Clin Oncol, 139, 645-652.

[2]   Kong, Y., Wang, J., Liu, W., Chen, Q., Yang, J., Wei, W., Wu, M., Yang, L., Xie, X., Lv, N., Guo, J., Li, L., Gao, J., Xie, X. and Dai, S. (2013) Cytokeratin19-2g2, a Novel Fragment of Cytokeratin19 in Serum, Indicating a More Invasive Behavior and Worse Prognosis in Breast Cancer Patients. PLoS ONE, 8, e57092.

[3]   Fisher, E.R., Land, S.R., Saad, R.S., Fisher, B., Wickerham, D.L., Wang, M., Costantino, J.P. and Wolmark, N. (2007) Pathologic Variables Predictive of Breast Events in Patients with Ductal Carcinoma in Situ. Am J Clin Pathol, 128, 86-91.

[4]   Lee, J.H., Suh, Y.J., Shim, B.Y. and Kim, S.H. (2011) The Incidence and Predictor of Lymph Node Metastasis for Patients with T1mi Breast Cancer Who Underwent Axillary Dissection and Breast Irradiation: An Institutional Analysis. Jpn J Clin Oncol, 41, 1162-1167.

[5]   Stackievicz, R., Paran, H., Bernheim, J., Shapira, M., Weisenberg, N., Kaufman, T., Klein, E. and Gutman, M. (2010) Prognostic Significance of HER-2/Neu Expression in Patients with Ductal Carcinoma in Situ. Isr Med Assoc J, 12, 290-295.

[6]   Shekhar, M.P., Tait, L., Pauley, R.J., Wu, G.S., Santner, S.J., Nangia-Makker, P., Shekhar, V., Nassar, H., Visscher, D.W., Heppner, G.H. and Miller, F.R. (2008) Comedo-Ductal Carcinoma in Situ: A Paradoxical Role for Programmed Cell Death. Cancer Biol Ther, 7, 1774-1782.

[7]   Lehr, H.A., Rochat, C., Schaper, C., Nobile, A., Shanouda, S., Vijgen, S., Gauthier, A., Obermann, E., Leuba, S., Schmidt, M.C.C.R., Delaloye, J.F., Simiantonaki, N. and Schaefer, S.C. (2013) Mitotic Figure Counts Are Significantly Overestimated in Resection Specimens of Invasive Breast Carcinomas. Modern Pathology, 26, 336-342.

[8]   Sarode, V.R., Han, J.S., Morris, D.H., Peng, Y. and Rao, R. (2011) A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma in Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy. International Journal of Breast Cancer, 2011, 1-7.

[9]   Bolton, K.L., Garcia-Closas, M., Pfeiffer, R.M., Duggan, M.A., Howat, W.J., Hewitt, S.M., Yang, X.R., Cornelison, R., Anzick, S.L., Meltzer, P., Davis, S., Lenz, P., Figueroa, J.D., Pharoah, P.D. and Sherman, M.E. (2010) Assessment of Automated Image Analysis of Breast Cancer. Tissue Microarrays for Epidemiologic Studies. Cancer Epidemiol Biomarkers, 19, 992-999.

[10]   Mohammed, Z.M.A., McMillan, D.C., Elsberger, B., Going, J.J., Orange, C., Mallon, E., Doughty, J.C. and Edwards, J. (2012) Comparison of Visual and Automated Assessment of Ki-67 Proliferative Activity and Their Impact on Outcome in Primary Operable Invasive Ductal Breast Cancer. British Journal of Cancer, 106, 383-388.

[11]   Konsti, J., Lundin, M., Joensuu, H., Lehtimäki, T., Sihto, H., Holli, K., Turpeenniemi-Hujanen, T., Kataja, V., Sailas, L., Isola, J. and Lundin, J. (2011) Development and Evaluation of a Virtual Microscopy Application for Automated Assessment of Ki-67 Expression in Breast Cancer. BMC Clinical Pathology, 11, 3-11.

[12]   Fasanella, S., Leonardi, E., Cantaloni, C., Eccher, C., Bazzanella, I., Aldovini, D., Bragantini, E., Morelli, L., Cuorvo, L.V., Ferro, A., Gasperetti, F., Berlanda, G., Dalla, Palma, P. and Barbareschi, M. (2011) Proliferative Activity in Human Breast Cancer: Ki-67 Automated Evaluation and the Influence of Different Ki-67 Equivalent Antibodies. Diagnostic Pathology, 6, S1- S7.

[13]   Johnson, R.H., Chien, F.L. and Bleyer, A. (2013) Incidence of Breast Cancer with Distant Involvement among Women in the United States, 1976 to 2009. JAMA, 309, 800-805.

[14]   Fayanju, O.M., Nwaogu, I., Jeffe, D.B. and Margenthaler, J.A. (2015) Pathological Complete Response in Breast Cancer Patients Following Neoadjuvant Chemotherapy at a Comprehensive Cancer Center: The Natural History of an Elusive Prognosticator. Mol Clin Oncol, 3, 775-780.

[15]   Baghestani, A.R., Shahmirzalou, P., Zayeri, F., Akbari, M.E. and Hadizadeh, M. (2015) Prognostic Factors for Survival in Patients with Breast Cancer Referred to Omitted Cancer Research Center in Iran. Asian Pac J Cancer Prev, 16, 5081-5084.